Background: Psoriatic arthritis (PsA) is a challenging heterogeneous disease. The European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and PsA (GRAPPA) last published their respective recommendations for the management of PsA in 2015. However, these guidelines are primarily based on studies conducted in resource replete countries and may not be applicable in countries in the Americas (except Canada and USA) and Africa. We sought to adapt the existing recommendations for these regions under the auspices of the International League of Associations for Rheumatology (ILAR). Process: The ADAPTE Collaboration (2009) process for guideline adaptation was followed to adapt the EULAR and GRAPPA PsA treatm...
OBJECTIVE: We aimed to compile evidence for the efficacy and safety of therapeutic options for the p...
Objectives: This study aims to establish the first national treatment recommendations by the Turkish...
Background: Since the publication of the European League Against Rheumatism recommendations for the ...
Published literature regarding the prevalence, incidence, management, and outcomes for psoriatic art...
Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatme...
To access publisher's full text version of this article click on the hyperlink at the bottom of the ...
Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatmen...
In 2015, both the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) an...
Objective: To update the European League Against Rheumatism (EULAR) recommendations for the pharmaco...
Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis ...
Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatmen...
Objectives Patient care can vary substantially by country. The objective was to explore differences ...
Objective: To update recommendations for the treatment of psoriatic arthritis with biological therap...
BACKGROUND: Information on the factors that influence treatment management decisions for psoriatic a...
At the 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthr...
OBJECTIVE: We aimed to compile evidence for the efficacy and safety of therapeutic options for the p...
Objectives: This study aims to establish the first national treatment recommendations by the Turkish...
Background: Since the publication of the European League Against Rheumatism recommendations for the ...
Published literature regarding the prevalence, incidence, management, and outcomes for psoriatic art...
Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatme...
To access publisher's full text version of this article click on the hyperlink at the bottom of the ...
Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatmen...
In 2015, both the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) an...
Objective: To update the European League Against Rheumatism (EULAR) recommendations for the pharmaco...
Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis ...
Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatmen...
Objectives Patient care can vary substantially by country. The objective was to explore differences ...
Objective: To update recommendations for the treatment of psoriatic arthritis with biological therap...
BACKGROUND: Information on the factors that influence treatment management decisions for psoriatic a...
At the 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthr...
OBJECTIVE: We aimed to compile evidence for the efficacy and safety of therapeutic options for the p...
Objectives: This study aims to establish the first national treatment recommendations by the Turkish...
Background: Since the publication of the European League Against Rheumatism recommendations for the ...